

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drugs in Development, 2021

<https://marketpublishers.com/r/P3BE6FC383C6EN.html>

Date: September 2021

Pages: 69

Price: US\$ 3,500.00 (Single User License)

ID: P3BE6FC383C6EN

Abstracts

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drugs in Development, 2021

SUMMARY

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Protein kinase C (PKC) is an enzyme belonging to a family of serine%li%and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis.

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 11 molecules. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 9 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders, Infectious Disease, Oncology and Ophthalmology which include indications Alzheimer's Disease, Ischemia Reperfusion Injury, Traumatic Brain Injury, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alcohol Addiction, Depression, Dry (Atrophic) Macular Degeneration, Fragile X Syndrome, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ischemic Stroke, Lymphoma, Multiple Sclerosis, Neurology, Parkinson's Disease, Pervasive Developmental Disorder (PDD), Rett Syndrome and Stroke.

The latest report Protein Kinase C Epsilon Type - Drugs In Development, 2021, outlays

comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)

The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects

The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Companies

Involved in Therapeutics Development

BryoLogyx Inc

CHS Pharma Inc

Synaptogenix Inc

VM Discovery Inc

Young Therapeutics LLC

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug
Profiles

Bryostatin-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Epsilon PKC for Ischemic Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate PKC Epsilon for Neurology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate PKC Epsilon for Pervasive Developmental Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PRKCE for HIV and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sulindac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMD-2202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YT-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones

Featured News & Press Releases

Jul 26, 2021: Synaptogenix discloses positive results of further Bryostatins trial analyses

in presentation at Alzheimer's Association International Conference 2021

Jul 14, 2021: Synaptogenix to present data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Jul 07, 2021: Synaptogenix announces regenerative patent award to treat Alzheimer's disease

Jun 09, 2021: Synaptogenix announces phase 2b NIH sponsored Alzheimer's disease trial update

Apr 01, 2021: Synaptogenix announces phase 2b Bryostatin-1 clinical trial update

Feb 04, 2021: Synthetic bryostatin available to expand neurodegenerative indication trials

Oct 13, 2020: BryoLogyx announces completion of world's first GMP synthesis of bryostatin-1

Oct 07, 2020: Neurotrope begins Phase II trial of Alzheimer's drug candidate

Aug 04, 2020: BryoLogyx announces cooperative research and development agreement for Bryostatin-1 with National Cancer Institute

Jul 30, 2020: Neurotrope Bioscience announces agreement with worldwide clinical trials, to conduct ongoing phase 2 study of Bryostatin-1, partially funded by NIH, for Alzheimer's Disease

Jun 10, 2020: Neurotrope announces strategic partnership with BryoLogyx for supply of synthetic Bryostatin-1 and continuation of the National Cancer Institute (NCI) trial for childhood leukemia

May 28, 2020: Neurotrope launches new long-term clinical trial of Bryostatin with the National Institutes of Health for the treatment of patients with Alzheimer's Disease

Jan 22, 2020: Neurotrope provides corporate update after completing Bryostatin-1 data analysis for advanced Alzheimer's disease trial

Sep 10, 2019: Neurotrope Alzheimer's Phase II trial fails to meet endpoints

Aug 13, 2019: Neurotrope announces publication highlighting the potential of bryostatin as a unique neurorestorative therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by BryoLogyx Inc, 2021

Pipeline by CHS Pharma Inc, 2021

Pipeline by Synaptogenix Inc, 2021

Pipeline by VM Discovery Inc, 2021

Pipeline by Young Therapeutics LLC, 2021

Dormant Projects, 2021

Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/P3BE6FC383C6EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P3BE6FC383C6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

